Re:Pfizer and BioNTech Conclude Phase 3 Study of Covid-19 Va...
by virtuallynathan on Wednesday November 18, 2020 @09:05AM
(#25136841)
I would agree, it probably not a good metric. Just providing some standard numbers for treatments.
Keep in mind the definition of a case here is having symptoms, so we don’t know if the vaccine prevents lightly symptomatic or asymptomatic cases, which may or may not result in transmission.
Keep in mind the definition of a case here is having symptoms, so we don’t know if the vaccine prevents lightly symptomatic or asymptomatic cases, which may or may not result in transmission.